In regard to Boccia et al.: assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP) (INT J RADIAT ONCOL BIOL PHYS 2004;60:302-309).

[1]  J. Bourhis,et al.  Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). , 2004, International journal of radiation oncology, biology, physics.

[2]  E. Winer,et al.  2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Brizel,et al.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Brizel.  Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. , 1998, Seminars in radiation oncology.

[5]  J. Cooper,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Büntzel,et al.  Radiochemotherapy with amifostine cytoprotection for head and neck cancer , 1998, Supportive Care in Cancer.